ABVX
$120.34-2.69 (-2.18%)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Recent News
2 Healthcare Stocks to Buy Before They Get Bought Out
Abivax and Nektar Therapeutics are clinical-stage biotech companies that would make attractive buyout targets.
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally
This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.